Spironolactone use in patients with heart failure

Journal of Clinical Pharmacy and Therapeutics

Volumn 29, Issue 2, 2004, Pages 165-170

  Trujillo, J M ^a   Gonyeau, M J ^a   DiVall, M V ^a   Alexander, S L ^b  

^a NORTHEASTERN UNIVERSITY   (United States)

^b ELI LILLY AND COMPANY   (United States)

Author keywords

Heart failure; Spironolactone; Treatment

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ATENOLOL; BENAZEPRIL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; CANDESARTAN; CAPTOPRIL; CARVEDILOL; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; FOSINOPRIL; FUROSEMIDE; HYDRALAZINE; HYDROCHLOROTHIAZIDE; IRBESARTAN; ISOSORBIDE DINITRATE; ISOSORBIDE MONONITRATE; LISINOPRIL; LOSARTAN; METOPROLOL; MOEXIPRIL; NITRATE; QUINAPRIL; RAMIPRIL; SPIRONOLACTONE; TORASEMIDE; VALSARTAN;

ADULT; AGED; DEMOGRAPHY; DRUG CONTRAINDICATION; DRUG HYPERSENSITIVITY; FEMALE; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; MEDICAL SERVICE; REVIEW; TEACHING HOSPITAL;

ADULT; AGED; AGED, 80 AND OVER; ALDOSTERONE ANTAGONISTS; CONCURRENT REVIEW; DRUG UTILIZATION REVIEW; FEMALE; HEART FAILURE, CONGESTIVE; HOSPITALS, TEACHING; HOSPITALS, URBAN; HUMANS; MALE; MASSACHUSETTS; MIDDLE AGED; PATIENT COMPLIANCE; RANDOMIZED CONTROLLED TRIALS; SEVERITY OF ILLNESS INDEX; SPIRONOLACTONE;

EID: 1842784955     PISSN: 02694727     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2710.2004.00549.x     Document Type: Review

References (12)

1. O'Connell JB (2000) The economic burden of heart failure. Clinical Cardiology, 23, III6-III10.
2. Weber KT (2001) Aldosterone in congestive heart failure. New England Journal of Medicine, 345, 1689-1697.
3. Pitt B, Zannad F, Remme WJ et al (1999) The effect of spironolactone on morbidity and mortality in patients with severe heart failure. New England Journal of Medicine, 341, 709-717.
4. Advisory Council to Improve Outcomes Nationwide in Heart Failure (ACTION-HF) (1999) Consensus recommendations for the management of congestive heart failure. American Journal of Cardiology, 83, 1A-38A.
5. Heart Failure Society of America (HFSA) practice guidelines (1999) HFSA guidelines for management of patients with heart failure caused by left ventricular systolic dysfunction-pharmacological approaches. Journal of Cardiac Failure, 5, 357-382.
6. Hunt SA, Baker DW, Chin MH, Cinquegrani MP, Feldman AM, Francis GS et al. (2001) ACC/AHA Guidelines for the evaluation and management of chronic heart failure in the adult: executive summary. Circulation, 104, 2996-3007.
7. Krumholz HM, Baker DW, Ashton CM, Dunbar SB, Friesinger GC, Havranek EP et al. (2000) Evaluating quality of care for patients with heart failure. Circulation, 101, e122-e140.
8. http://www.drugstore.com/pharmacy/prices/ drugprice.asp?ndc= 00781159901&trx=1Z5006.Last accessed on 25 June 2003.
9. The Large State Peer Review Organization Consortium (1997) Heart failure treatment with angiotensin-converting enzyme inhibitors in hospitalized medicare patients in 10 large states. Archives of Internal Medicine, 157, 1103-1108.
10. Smith NL, Psaty BM, Pitt B, Garg R, Gottdiener JS, Heckbert SR (1998) Temporal patterns in the medical treatment of congestive heart failure with angiotensin-converting enzyme inhibitors in older adults, 1989 through 1995. Archives of Internal Medicine, 158, 1074-1080.
11. Stafford RS, Saglam D, Blumenthal D (1997) National patterns of angiotensin-converting enzyme inhibitor use in congestive heart failure. Archives of Internal Medicine, 157, 2460-2464.
12. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B et al. (2003) Elprenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. New England Journal of Medicine, 348, 1309-1321.